title: Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
authors.affiliation: Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
authors.forename: J F
authors.initials: JF
authors.lastname: Smyth
authors.forename: J D
authors.initials: JD
authors.lastname: Hardcastle
authors.forename: G
authors.initials: G
authors.lastname: Denton
authors.forename: D
authors.initials: D
authors.lastname: Alderson
authors.forename: R H
authors.initials: RH
authors.lastname: Grace
authors.forename: J L
authors.initials: JL
authors.lastname: Mansi
authors.forename: H M
authors.initials: HM
authors.lastname: Yosef
authors.forename: O
authors.initials: O
authors.lastname: Nordle
authors.forename: H
authors.initials: H
authors.lastname: Lauri
authors.forename: S
authors.initials: S
authors.lastname: Wählby
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D011788:Quality of Life; D012044:Regression Analysis; D015996:Survival Rate; D013654:Taurine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D013654:Taurine; C052991:1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea; D005472:Fluorouracil